Study on achievement of target LDL-C in Dyslipidemic patients
Journal Title: International Journal of Research in Pharmacology & Pharmacotherapeutics (IJRPP) - Year 2013, Vol 2, Issue 1
Abstract
Cardiovascular diseases are the leading cause of illness and morbidity in developing and developed countries. The majority of cardiovascular cases stem from atherosclerosis and epidemiological studies have identified dyslipidemia is the prime etiology for the atherosclerosis. A prospective observational study was conducted at a multispecialty hospital in the General Medicine and Cardiology departments for a period of 8 months. The study was carried among 80 dyslipidemic patients. From the lipid profile data it was found that 15(18.75%) patients LDL-C found to be above optimum level, 5(6.25%) patients LDL-C found to be borderline high, majority of the patients 42(52.5%) were found to have high LDL-C levels and 18(22.5%) patients LDL-C was found to be very high. All the study population required drug therapy as per ATP III guidelines of NCEP. The majority of patients (95%) were receiving lipid lowering therapy with statins and rest of the patients was on combination therapy. The patients were categorized based on the risk factors, 40 (50%) as CHD group, 34 (42.5%) as high risk non CHD group and 6 (7.5%) belongs to low risk non CHD group. For the high risk non CHD group ten year risk percentage for having CHD was calculated and the results reveal that 3(8.8%) patients were found to have <10% of risk for CHD, 10(29.4%) patients has 10-20% of risk for CHD and 21(61.8%) patients have >20% of risk for CHD. Based on the risk groups assessment of target LDL-C was performed and the results reveals that 22.5% of study population achieved the target LDL-C described by ATP III guideline, which was found to be unsatisfactory. The study results necessitates the need for more aggressive management is required to attain target LDL-C levels. The pharmaceutical care can be the key for successive lipid lowering therapy.
Authors and Affiliations
V. Shivashankar V. Shivashankar
Keywords
Related Articles
- EP ID EP411875
- DOI -
- Views 103
- Downloads 0
Antioxidant and Antitumor Activities on Catunaregum spinosa.
The methanol extract of Catunaregum spinosa (MECS) were evaluated for antitumor activity and antioxidant activity against Dalton’s ascites lymphoma (DAL) bearing Swiss albino mice. The extract was administered at the d...
Study of non-invasive predictors of oesophageal varices in chronic liver disease
Esophageal varices (EVs) are a serious consequence of portal hypertension in patients with liver diseases. Several studies have evaluated possible noninvasive markers of EVs to reduce the number of unnecessary endoscopie...
In vitro cytotoxic activity of ethanolic extract of Triumfetta rhomboidea against different cancer cell lines
Triumfetta rhomboidea (TR) is being used in traditional medicine for a variety of ailments. It is widely distributed in tropical and subtropical part of India up to an elevation of 1,200 m in the Himalayas. Triumfetta r...
Prevalence and treatment of malaria during the AIDS infection in hospital area of Bamako, Mali
Malaria and HIV are a major public health problem in developing countries. Our study was a prospective study to find the incidence of malaria during HIV infection in Bamako at the national referral and teaching hospital...
Quality by design approach to analytical method development for simultaneous estimation of ibuprofen and famotidine in their combined dosage form by RP-HPLC method
This article aims to explain the steps for application of quality by design (QbD) concept to analytical method development and validation, by using an example of simultaneous determination of Famotidine and Ibuprofen in...